Home › Hypertrophic Cardiomyopathy › NCT07755904
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Active-Comparator-Controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Diagnosed with oHCM per the protocol specified criteria * NYHA Class II or III at screening visits * KCCQ-CSS that meets the protocol specified criteria at screening visits * Adequate acoustic windows for echocardiography Key Exclusion Criteria: * Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation * History of intolerance or medical contraindication to β-blocker therapy * Resting systolic blood pressure (SBP) of \>160 millimeters of mercury (mmHg) at screening visits * Resting heart rate of \>100 beats per minute (bpm) at screening visits * Significant valvular heart disease, defined as: * Moderate to severe valvular aortic stenosis or fixed subaortic obstruction; * Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment) Other protocol-defined criteria apply.
About the study
The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.
What is being tested
- BHB-1893 (drug)
- Metoprolol (drug)
Sponsor: Braveheart Bio, Inc. · Participants: 210 · Started: Sep 2, 2026
Contact the study team
- Study Director · Phone: (415) 707-6312
Official record on ClinicalTrials.gov — NCT07755904
Locations in the U.S.
| New York | LIONHEART-HCM Site 0107, Manhasset |
| South Carolina | LIONHEART-HCM Site 0126, Rock Hill |
| Texas | LIONHEART-HCM Site 0121, Plano |
Conditions
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.